Bladder News and Research

RSS

German researchers discover miRNAs, which determine malignancy of urinary bladder cancers

German researchers have identified four biomarkers that correctly determine malignancy of urinary bladder cancers and contribute to the accurate prediction of patient outcomes. Their results are published in the September issue of The Journal of Molecular Diagnostics.

16 Aug 2013

Risk for childhood cancer moderately increased among adolescents with major birth defects

A multistate study led by researchers at the University of Utah has revealed that the risk for childhood cancer is moderately increased among children and young adolescents with certain types of major birth defects.

12 Aug 2013

Immune function restored in spinal injured mice

In a new study, researchers at The Center for Brain and Spinal Cord Repair at The Ohio State University Wexner Medical Center show that is possible to restore immune function in spinal injured mice.

7 Aug 2013

Targacept reports net loss of $12.4 million for Q2 2013

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics, today reported its financial results for the second quarter and six months ended June 30, 2013.

6 Aug 2013

Combating antibiotic resistance: an interview with Ron Najafi, CEO NovaBay Pharmaceuticals

Approximately 80 years ago the first antibiotic was discovered by Sir Alexander Fleming, for which he was justifiably awarded the Nobel Prize in medicine.

2 Aug 2013

Research identifies important mechanism behind bladder cancer

Bladder cancer is a common condition - an estimated 10,000 people are diagnosed with the disease each year in the UK. It is the seventh most common cancer in the UK, affecting men more than women.

1 Aug 2013

Researchers identify stem cells in urine can be directed to become multiple cell types

Could harvesting stem cells for therapy one day be as simple as asking patients for a urine sample? Researchers at Wake Forest Baptist Medical Center's Institute for Regenerative Medicine and colleagues have identified stem cells in urine that can be directed to become multiple cell types.

31 Jul 2013

Mda-9/syntenin helps regulate bladder cancer growth and metastasis

Scientists from Virginia Commonwealth University Massey Cancer Center have provided evidence from preclinical experiments that a gene known as melanoma differentiation associated gene-9/syntenin (mda-9/syntenin) could be used as a therapeutic target to kill bladder cancer cells, help prevent metastasis and even be used to non-invasively diagnose the disease and monitor its progression.

25 Jul 2013

Study: Cannabis has no effect in slowing course of progressive multiple sclerosis

The first large non-commercial clinical study to investigate whether the main active constituent of cannabis (tetrahydrocannabinol or THC) is effective in slowing the course of progressive multiple sclerosis (MS), shows that there is no evidence to suggest this; although benefits were noted for those at the lower end of the disability scale.

24 Jul 2013

Researchers develop reliable way to use finger-stick blood sample to detect fibromyalgia syndrome

Researchers have developed a reliable way to use a finger-stick blood sample to detect fibromyalgia syndrome, a complicated pain disorder that often is difficult to diagnose.

24 Jul 2013

Patients with post-stroke detrusor overactivity show positive outcomes after electroacupuncture

Detrusor overactivity is common after stroke, and is characterized by frequent micturition and urinary incontinence. However, the optimal treatment for post-stroke detrusor overactivity remains unclear.

23 Jul 2013

Fujikura to exercise option to license Cellmid’s midkine diagnostic technology

Cellmid Limited has received confirmation that Fujikura Kasei Co Ltd (Fujikura) will exercise its Option to licence the midkine (MK) diagnostic technology by paying the requisite JPY40 million (AUD 440,000) Milestone Fee.

22 Jul 2013

Elekta gets CE Mark approval for Clarity 4D Monitoring system

Elekta has received CE marking for its Clarity 4D Monitoring system permitting European clinics to implement this new way of reducing the uncertainty caused by prostate motion during radiation treatment. Physicians will be able to monitor the motion of the prostate with sub millimeter accuracy during the delivery of therapeutic radiation beams.

From Elekta 19 Jul 2013

TAp73 protein frequently overexpressed in wide range of human tumors

They say you can pick your friends, but not your family. The same may hold true for related proteins. The protein TAp73 is a relative of the well-known, tumor-suppressor protein p53. It shares extensive common gene sequences with p53 and, as suggested by some previous studies, it may function similar to p53 to prevent tumor formation.

17 Jul 2013

OncoGenex completes enrollment in OGX-427 Phase 2 trial for treatment of metastatic bladder cancer

OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.

16 Jul 2013

FDA approves Gilotrif for patients with late stage non-small cell lung cancer

Companion test also approved to identify appropriate patients The U.S. Food and Drug Administration today approved Gilotrif (afatinib) for patients with late stage (metastatic) non-small cell lung cancer (NSCLC) whose tumors express specific types of epidermal growth factor receptor (EGFR) gene mutations, as detected by an FDA-approved test. Lung cancer is the leading cause of cancer-related death among men and women.

16 Jul 2013

Proteins involved in immunity produce cancer-causing DNA mutations, study finds

A set of proteins involved in the body's natural defenses produces a large number of mutations in human DNA, according to a study led by researchers at the National Institutes of Health. The findings suggest that these naturally produced mutations are just as powerful as known cancer-causing agents in producing tumors.

15 Jul 2013

Researchers discover that APOBEC3B is important cancer mutagen

Researchers at the University of Minnesota have discovered that a human antiviral enzyme causes DNA mutations that lead to several forms of cancer.

15 Jul 2013

Robotic retroperitoneal lymph node dissection (RPLND) for testicular cancer: an interview with Dr. Stephen Williams of St. Joseph Hospital in Orange

Robotic RPLND utilizes laparoscopy combined with robotic technology to perform dissection and removal of lymph node tissue in the retroperitoneum both as a staging as well as therapeutic procedure for patients with testicular cancer.

10 Jul 2013

Bioniche, Paladin close debt refinancing agreement and sign first licensing deal for Urocidin

Bioniche Life Sciences Inc. and Paladin Labs Inc. today announced the official closing of the various agreements associated with a comprehensive strategic collaboration to refinance and increase Bioniche's debt, provide new equity, and enter into the first licensing deal for Bioniche's Phase III bladder cancer product - Urocidin.

6 Jul 2013